https://www.veteransasbestosalliance.org/items/nivolumab-and-ipilimumab-in-treating-patients-with-rare-tumors 2023-01-15 https://www.veteransasbestosalliance.org/items/durvalumab-with-chemotherapy-as-first-line-treatment-in-advanced-pleural-mesothelioma 2023-01-13 https://www.veteransasbestosalliance.org/items/study-of-tbio-6517-given-alone-or-in-combination-with-pembrolizumab-in-solid-tumors 2023-01-15 https://www.veteransasbestosalliance.org/items/safety%2C-tolerability%2C-pharmacokinetics%2C-and-pharmacodynamics-of-incb099280-in-participants-with-advanced-solid-tumors 2023-01-13 https://www.veteransasbestosalliance.org/items/intratumor-injection-of-anti-mesothelin-immunotoxin-lmb-100-with-ipilimumab-in-malignant-mesothelioma 2023-01-13 https://www.veteransasbestosalliance.org/items/safety%2C-tolerability%2C-pharmacokinetics%2C-and-pharmacodynamics-of-incb099318-in-participants-with-advanced-solid-tumors 2023-01-15 https://www.veteransasbestosalliance.org/items/a-study-of-immunotherapy-drugs-nivolumab-and-ipilimumab-in-patients-w%2Fresectable-malignant-peritoneal-mesothelioma 2023-01-13 https://www.veteransasbestosalliance.org/items/the-registry-of-oncology-outcomes-associated-with-testing-and-treatment 2023-01-13 https://www.veteransasbestosalliance.org/items/a-beta-only-il-2-immunotherapy-(ability)-study 2023-01-13 https://www.veteransasbestosalliance.org/items/stereotactic-body-radiation-therapy-with-immunotherapy-for-the-treatment-of-mesothelioma 2023-01-13 https://www.veteransasbestosalliance.org/items/chemotherapy-with-or-without-immunotherapy-for-peritoneal-mesothelioma 2023-01-13